我們已在上線！進一步了解

KORU Medical Systems

KRMD

市值 US$1.39億

3.00 USD

-0.03

0.99%

收盤時已更新 10月16日下午4:00 EDT

1天

-0.99%

5天

1.35%

1個月

-6.25%

3個月

-29.25%

6個月

-28.23%

今年迄今

-46.52%

1年

-25.37%

5年

9.09%

10年

-24.43%

關於： KORU Medical Systems Inc develops, manufactures, and commercializes large volume subcutaneous infusion solutions for the subcutaneous drug delivery market. Its product portfolio focuses on mechanical infusion devices, including the FREEDOM60 and FreedomEdge syringe drivers, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing. The company operates as one segment. Its revenue streams are: Domestic Core, International Core and Pharma services and clinical trials. The majority of the company's revenue is derived from the Domestic Core business, which consists of sales of its syringe drivers, tubing and needles. Geographically, its revenues are predominantly derived from the United States.

員工： 73

醫療保健醫療器材與用品

新聞

正面

中性

負面

市場情緒 3個月

正面 33.3%

中性 66.7%

負面 0%

KORU Medical Systems, Inc. (KRMD) Q2 2026 Earnings Call Transcript

KORU Medical Systems, Inc. (KRMD) Q2 2026 Earnings Call Transcript

KORU Medical Systems, Inc. (KRMD) Q2 2026 Earnings Call Transcript

KORU Medical Systems Q2 Earnings Call Highlights

KORU Medical Systems NASDAQ: KRMD reported second-quarter revenue of $12 million, up 18% from a year earlier, as domestic patient starts, market-share gains and international demand supported growth. The company also said it achieved positive net income for the first time since 2019 and raised its full-year gross-margin outlook, while narrowing revenue guidance because certain international prefilled-syringe market launches are taking longer to develop than expected.

KORU Medical Systems Q2 Earnings Call Highlights

Zacks Investment Research

KORU Medical Systems, Inc. (KRMD) Q2 Earnings and Revenues Beat Estimates

KORU Medical Systems, Inc. (KRMD) came out with quarterly earnings of $0.01 per share, beating the Zacks Consensus Estimate of a loss of $0.02 per share. This compares to break-even earnings per share a year ago.

KORU Medical Systems, Inc. (KRMD) Q2 Earnings and Revenues Beat Estimates

KORU Medical Systems Announces Second Quarter 2026 Results and Updates Full Year 2026 Guidance

MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today reported financial results for the second quarter ended June 30, 2026. The Company also updated guidance for the full year 2026. Second Quarter 2026 and Recent Highlights Net revenues grew 18% over the p.

KORU Medical Systems Announces Second Quarter 2026 Results and Updates Full Year 2026 Guidance

KORU Medical Systems to Participate in the Canaccord Genuity 46th Annual Growth Conference

MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that the Company will participate in the Canaccord Genuity 46th Annual Growth Conference on August 12th, 2026. KORU Medical's management is scheduled to present at the Canaccord Genuity 46th Annual.

KORU Medical Systems to Participate in the Canaccord Genuity 46th Annual Growth Conference

Kaskela Law LLC Announces Investigation of KORU Medical Systems, Inc. (KRMD) and Encourages Long-Term KRMD Shareholders to Contact the Firm

PHILADELPHIA--(BUSINESS WIRE)--Kaskela Law is investigating KORU Medical Systems, Inc. (Nasdaq: KRMD) (“KORU”) on behalf of the company's current shareholders.The investigation seeks to determine whether KORU and/or the company's officers and directors violated the securities laws or breached their fiduciary duties in connection with recent corporate actions.KORU shareholders are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq. or Adrienne Bell, Esq.) for additional information abo.

Kaskela Law LLC Announces Investigation of KORU Medical Systems, Inc. (KRMD) and Encourages Long-Term KRMD Shareholders to Contact the Firm

KORU Medical Systems to Report Second Quarter 2026 Financial Results on August 5, 2026

MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that the Company will report second quarter 2026 financial results on Wednesday, August 5, 2026. KORU Medical's management will host a conference call and webcast at 4:30 p.m. ET that day to discus.

KORU Medical Systems to Report Second Quarter 2026 Financial Results on August 5, 2026

KORU Medical Systems Presents Real World Data on the Benefits of the FreedomEDGE Syringe Infusion System in Infusion Clinics at the 51st Annual Oncology Nursing Society Congress

MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on innovative and patient-centric large volume subcutaneous infusion solutions, today announced that the Company presented its latest research at the Oncology Nursing Society (ONS) Congress, May 13-17. The poster at ONS was titled, “Reducing Ergonomic Strain During Subcutaneous Monoclonal Antibody Administration.” The ONS abstract evaluated nur.

KORU Medical Systems Presents Real World Data on the Benefits of the FreedomEDGE Syringe Infusion System in Infusion Clinics at the 51st Annual Oncology Nursing Society Congress

KORU Medical Systems, Inc. (KRMD) Q1 2026 Earnings Call Transcript

KORU Medical Systems, Inc. (KRMD) Q1 2026 Earnings Call Transcript

KORU Medical Systems, Inc. (KRMD) Q1 2026 Earnings Call Transcript

Zacks Investment Research

KORU Medical Systems, Inc. (KRMD) Reports Q1 Loss, Tops Revenue Estimates

KORU Medical Systems, Inc. (KRMD) came out with a quarterly loss of $0.02 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.03 per share a year ago.

KORU Medical Systems, Inc. (KRMD) Reports Q1 Loss, Tops Revenue Estimates

查看新聞排名

價格圖表採用Lightweight Charts™實作